What is Scientia Clinical Research?
Scientia Clinical Research is the first purpose-built, publicly funded clinical trials facility in NSW. We have the infrastructure to perform both first-in-human and first-in-patient studies, as well as later phase studies, across a wide range of therapeutic disciplines, including oncology and haematology.
We are co-located within a major research precinct with Prince of Wales Hospital, Sydney Children’s Hospital, Royal Hospital for Women, UNSW Sydney and the Lowy Cancer Research Centre. Scientia will foster collaboration with scientists and clinical researchers as well as the pharmaceutical industry to improve health.
Why Scientia Clinical Research?
We have the services and facilities to partner with you from study design through to study close-out.
30 inpatient beds
Central Cardiac Monitoring System including continuous 12-ECG and SpO2 telemetry
17 private consulting rooms
2 procedure rooms with video/multimedia capabilities
On-site Pharmacy with GMP compliant clean room for aseptic, cytotoxic and GMO preparation
Hospital Emergency Department services at call
Lounge, dining and recreation areas for participants
Waiting areas, offices, and stores
Multiple meeting rooms
Board room with videoconferencing and multimedia capabilities
Conduct of phase I-IV clinical trials
Protocol and clinical study report development
Investigator brochure preparation
Informed consent development
Preparation and submission of ethics and regulatory (TGA) submission
Project planning and management
Sample processing and analysis
Scientia Clinical Research has access to a broad range of medical and surgical services from the onsite Prince of Wales Hospital.
Scientia Clinical Research has a comprehensive risk-based QMS to ensure delivery of services to the highest standards in alignment with:
- GCP, cGMP and GLP
- 21 CFR 11
- all relevant regulatory requirements (e.g. TGA, FDA, EMA)
There are many advantages to completing your early phase trial in Sydney, Australia. In Sydney, you will benefit from:
- A fast track regulatory approval system for Phase I trials
- A generous research and development tax incentive system
- An ethnically diverse population, enabling trials within different ethnic groups (including Japanese)
- High-quality healthcare infrastructure
- 7.6 million people (in Australia’s most populous city) and a high volunteer participation rate